GUANGZHOU, China, May 8, 2026 /PRNewswire/ — The 139th Canton Fair concluded on May 5, setting a new record for overseas buyer attendance. Data from the China Foreign Trade Centre show that across 15 days and three phases, the fair welcomed a record 314,000 overseas buyers from 220 countries and regions who came to explore opportunities at “China’s No. 1 Fair.”

Inside the Canton Fair venue, the “PHYBOT C2” bipedal humanoid robot, capable of playing badminton, handles challenges from buyers with ease.

The event covered about 1.55 million square meters with 75,700 booths. More than 32,000 exhibitors participated, including about 3,900 first-time exhibitors. Over 4.65 million products were on display; new products, green products, and products with independent intellectual property rights accounted for 23%, 22%, and 25%, respectively — reflecting the “new, green and smart” direction of “Made in China” and “Made in Guangdong.”

During the fair, organizers held more than 600 new-product launch events. The number of new products introduced rose 27%, and events for emerging future industries increased 30%. The fair also showcased AI-enabled scenarios for the first time, including robotic patrol inspections and drone flight demonstrations.

Nine specialized exhibition zones were newly established for this session. Phase I featured zones for consumer drones, agricultural drones, smart wearables and display technology. Phase II debuted zones for bamboo and wood household products and tableware, integrated housing and outdoor facilities, and trendy accessories. Phase III added a zone for functional and technical fabrics. Nearly 670 enterprises took part in these specialized zones, erecting more than 1,300 booths and highlighting innovative developments across industries.

Guangdong province got off to a strong start in foreign trade this year. In the first quarter, its import and export volume, national share, incremental growth and contribution rate all ranked first in China. Exports reached 1.53 trillion yuan, up 14.3%, while imports reached 1.01 trillion yuan, up 27.8%. Import growth was broad-based, led by the “old three” — mobile phones, computers and home appliances — as well as garments and luggage. At the same time, the province advanced its “new three” products: exports of 3D printers, drones and digital cameras rose 136.9%, 51.2% and 60.2%, respectively. These products of new quality productive forces have received popularity worldwide. Exports of self-owned brands grew 38%, raising their share of Guangdong’s total export value in the first quarter to 26.6%.

As a vital window into China’s opening-up and a barometer of its foreign trade, the Canton Fair has evolved alongside the Chinese economy over its 70-year history. This session’s successful conclusion complemented Guangdong’s robust start in foreign trade. Many Guangdong enterprises used the Canton Fair platform to engage directly with global buyers and secure international orders, helping Guangdong maintain its top national ranking in foreign trade scale. In turn, Guangdong’s thriving development continuously injects vitality into the Canton Fair. The major foreign trade province’s strong industrial base, comprehensive supply chain and innovative products and technologies continue to sustain the fair’s global influence.

Source

CHENGDU, China, May 8, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”) announced that the sNDA (the “Application”) for the Company’s TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. The application is for sac-TMT in combination with MSD’s^[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[2]) as first‑line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative. This acceptance is based on the positive results from the OptiTROP-Lung05 registrational Phase III study, and the application is the fifth indication application for sac-TMT that has been accepted by the NMPA.

The OptiTROP-Lung05 is a randomized, open-label, multicenter, Phase III clinical study that evaluates the efficacy and safety profile of sac-TMT in combination with pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-positive locally advanced or metastatic NSCLC. At a pre-specified interim analysis, the study has met its primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement as concluded by the Independent Data Monitoring Committee (IDMC). A positive trend in overall survival (OS) was also observed. Notably, the OptiTROP-Lung05 study is the first Phase III study of an immunotherapy and ADC combination to meet its primary endpoint in first-line NSCLC treatment. The study has been selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract number #8506, Lung Cancer –Non-Small Cell Metastatic).

Previously, sac-TMT in combination with intravenous and subcutaneous pembrolizumab for the first-line treatment of patients with locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative was granted Breakthrough Therapy Designation (BTD) by the NMPA. On April 9, 2026, the CDE’s official website announced that the Application has entered the priority review and approval process. This marks the fifth sac-TMT indication to enter the CDE’s priority review and approval process. Through this process, the review time will be significantly shortened, potentially expediting its approval pathways.

Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA^® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit in OS. This achievement holds significant importance for improving current treatment regimens for lung cancer. We will continue to collaborate with our partners to advance the clinical development and commercialization of sac-TMT, to help more patients with lung cancer and enhance their survival outcomes.”

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD has initiated 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

Source

BEIJING, May 8, 2026 /PRNewswire/ — Sohu.com Limited (NASDAQ: SOHU), a leading Chinese online media platform and game business group, will report its first quarter 2026 unaudited financial results on Monday, May 18, 2026, before U.S. market hours.

Sohu’s management team will host a conference call on the same day at 5:00 a.m. U.S. Eastern Time, May 18, 2026 (5:00 p.m. Beijing/Hong Kong time, May 18, 2026) following the quarterly results announcement.

Conference Call Preregistration

Participants can register for the conference call by clicking here, you will be led to the conference registration website. Upon registration, each participant will receive details for the conference call, including dial-in numbers and a unique access PIN. Please dial in 10 minutes before the call is scheduled to begin.

The live webcast and archive of the conference call will be available on the Investor Relations section of Sohu’s website at https://investors.sohu.com/.

About Sohu

Sohu.com Limited (NASDAQ: SOHU) was established by Dr. Charles Zhang, one of China’s internet pioneers, in the 1990s. Sohu operates one of the leading Chinese online media platforms and also engages in the online game business in the Chinese mainland. Sohu has built one of the most comprehensive matrices of Chinese language web properties, consisting of Sohu News App, Sohu Video App, the mobile portal m.sohu.com, the PC portal www.sohu.com, and the online games platform www.changyou.com/en/.

As a mainstream media platform with social features, Sohu is indispensable to the daily life of millions of Chinese, providing to a vast number of users a network of web properties and community based products, which offer a broad array of content, such as news and information, in the form of text, picture, video, and live broadcasting. Sohu also attracts users to actively engage in content generation and distribution, and actively interact with each other on the platform. Sohu’s online game business is conducted by its subsidiary Changyou, which develops and operates a diverse portfolio of PC and mobile games, such as the well-known Tian Long Ba Bu (“TLBB”) PC and Legacy TLBB Mobile.

For investor and media inquiries, please contact:

Sohu.com Limited
Ms. Pu Huang
Tel:        +86 (10) 6272-6645
E-mail:   ir@contact.sohu.com

Christensen Advisory 
E-mail:  sohu@christensencomms.com

Source

ABU DHABI, UAE, May 7, 2026 /PRNewswire/ — Speaking at Milken Institute Global Conference, one of the most influential cross-sector forums convening leaders in policy, investment and innovation, H.E. Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DOH), invited global partners, investors and innovators to, “build, test and scale next-generation health solutions in Abu Dhabi.”

H.E.Mansoor Al Mansoori- Reimagining Healthcare, for Abu Dhabi and Beyond Session

Al Mansoori positioned Abu Dhabi as a global test-bed for AI-enabled for real-world health innovation, underpinned by a fully integrated, intelligent health infrastructure, “AI, for us, is not hype, it is a utility. We are accelerating drug discovery by integrating comprehensive data like genotype, phenotype, and information from wearables into an AI-enabled system. This intelligent platform acts as a real-world evidence engine, allowing companies to assess product impact in real-time…Abu Dhabi is a ‘living lab’, and the invitation is open.”

Al Mansoori continued, “Every health system needs to have foresight, it is a responsibility. In Abu Dhabi, our intelligence-based system integrates all types of health data into one single platform that gives full visibility…so you can have the pulse of your system at any time.”

He highlighted the role of AI Agents within the emirate’s Unified Medical Operations Command Centre (UMOC) in creating foresight and resilience, “the UMOC is the ‘health brain’ of our system. Today, [with AI Agents] we have forty times the manpower of our workforce, detecting incidents in real-time, enabling faster emergency response, care that starts in the ambulance and creating a continuous intelligence loop.”

Al Mansoori continued, “Over the past period, our system didn’t pause. We kept going, delivering and accelerating. Abu Dhabi’s long-term plan in health, and in general, is grounded in economic diversification, strategic investment in technology and infrastructure, investing in people, empowered by deep capital reserve.”

On the sidelines of the conference, Al Mansoori also met with a select group of leaders in longevity, AI, biotechnology, paediatrics, genomics and investment during a dinner hosted under the Future Health – A Global Initiative by Abu Dhabi platform. The discussion focused on advancing practical models for anticipatory health systems, expanding equitable access to predictive care, and exploring new financing models that prioritise long-term health outcomes.

To watch the full conversation, please click here.

Source

Huawei’s Bangkok Launch Ignites All-Scenario Intelligence, Opening a New Chapter of Smart Life

BANGKOK, May 7, 2026 /PRNewswire/ — On May 7, 2026, Huawei held the “Now Is Your Spark” global product launch in Bangkok, Thailand, where they officially unveiled the HUAWEI MatePad Pro Max, HUAWEI WATCH FIT 5 Series, HUAWEI WATCH GT Runner 2 Racing Legend Edition, and other innovative products. With all-scenario technology, these devices serve as a genuine extension for global users to explore the world and express themselves.

An ultra-slim flagship tablet setting new benchmarks in mobile productivity

Huawei globally debuted the HUAWEI MatePad Pro Max at this launch. Combining refined design, a premium display, PC-level productivity, and a full suite of creative tools, the HUAWEI MatePad Pro Max provides flagship tablet performance in a remarkably thin and light form factor. At 499g and measuring a mere 4.7 mm thick, even the exclusive PaperMatte Edition weighs just 509g, HUAWEI MatePad Pro Max is the thinnest and lightest tablet among the 13-inch+ tablet.

Smart wearables refreshed for the next generation

Huawei has introduced a fresh lineup of smart wearables tailored for the young generation. The HUAWEI WATCH FIT 5 Series retains its iconic square design, now enhanced with a sleek, vibrant aesthetic. It guides users through engaging and accessible mini-workouts, encouraging a more active lifestyle. The series also supports a wide range of competitive sports, including cycling, golf, trail running, and tennis. With advanced tracking, analysis, and guidance features, it caters to diverse needs, from daily fitness routines to competitive sport.

Debuting at this event, the HUAWEI WATCH GT Runner 2 Racing Legend Edition is a professional running watch that embodies the look and feel of marathon racing. It features a new single running ability index (RAI) and a professional Training Camp Dashboard, giving runners deeper data insights to train smarter and race harder.

Huawei partnered with renowned jewelry designer Francesca Amfitheatrof to launch the HUAWEI WATCH ULTIMATE DESIGN Spring Edition. Inspired by the blooming beauty of spring, this design features 99 natural diamonds and diamond-cut sapphire glass, a wearable celebration of feminine strength and vitality.

Huawei has also unveiled new premium flagship kids watches: the HUAWEI WATCH KIDS X1 Series. Equipped with a front and rear high-definition camera setup, it features a 110° ultra-wide-angle front camera and a 1.82-inch AMOLED screen, offering a larger display and broader field of view. The device also includes a detachable and rotatable device body and AR fun feature, enabling kids to capture every precious moment of their explorations.

A new phone experience for the diverse needs of young users

Huawei officially launched the HUAWEI nova 15 Max, redefining the experience for a generation that plays hard and shoots sharp. Equipped with a 50 MP RYYB Ultra Vision Camera, it delivers true-to-life colors even in low light or backlit conditions. The 8,500 mAh Super Battery powers all-day use, eliminating battery anxiety. The Extra-Durable Body is drop-resistant, so everyday bumps are no longer a worry. Combined with a Vivid OLED Screen and Symmetrical Stereo Dual Speakers, an immersive audio-visual experience is always within reach. From photography to battery life, and from durability to audio-visuals, the HUAWEI nova 15 Max continuously empowers every passion.

From flagship tablets to smartwatches designed for children, Huawei’s connected device ecosystem continues to expand its presence in the daily lives of users around the world. Huawei remains committed to technology that is not only useful, but genuinely enriching, technology that ignites inspiration. Huawei looks forward to continued collaboration with users around the world, helping people live and work better, wherever they are.

Source